Giovanna Cutrona

@ospedalesanmartino.it

UO Molecular Pathology
IRCCS Ospedale Policlinico San Martino

Giovanna Cutrona


                  Download Compact PDF  
https://researchid.co/giovannacutrona

RESEARCH INTERESTS

Leukemia/Lymphoma
147

Scopus Publications

6326

Scholar Citations

42

Scholar h-index

111

Scholar i10-index

Scopus Publications

  • Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort
    Davide Bagnara, Andrea Nicola Mazzarello, Monica Colombo, Ennio Nano, Niccolò Cardente, Fabiana Ferrero, Nadia Bertola, Vanessa Cossu, Fabio Ghiotto, Adalberto Ibatici, Emanuele Angelucci, Antonino Neri, Massimo Gentile, Fortunato Morabito, Manlio Ferrarini, Giovanna Cutrona, Franco Fais
    Antibodies, 2026
    Background/Objectives: The immunoglobulin heavy-chain variable (IGHV) gene repertoire represents a characteristic feature of chronic lymphocytic leukemia (CLL), although its configuration is not well defined at the early disease stages. The IGHV repertoire of a cohort of early CLL patients was analyzed and compared to that of a “real-world” reference cohort. Methods: Patients from the O-CLL1 observational protocol, which enrolled only Binet stage A cases within twelve months from diagnosis, were studied. IGHV/IGHJ rearrangements were sequenced and annotated following ERIC recommendations, and stereotyped subsets were assigned using ARResT/AssignSubsets. The repertoire features were compared with the dataset of a real-world cohort of patients with heterogeneous staging (CTR cohort) and with published early-diagnosis series. Results: IGHV and IGHJ gene distributions and HCDR3-length profiles in O-CLL1 closely mirrored those of CTR, indicating that the BcR IG repertoire at diagnosis is already defined rather than being selected during disease progression. Mutated IGHV (M-CLL) predominated, with a frequency of stereotyped BcR IG comparable to that of other early-diagnosis cohorts. However, within this conserved framework, subset #4 was over-represented among M-CLL from O-CLL without an increased overall IGHV4-34 gene usage, suggestive of a selective expansion rather than a recombinational bias. Subset #4 cases retained canonical HCDR3 motifs and showed time-to-first-treatment like other M-CLL, likely reflecting the younger age structure of O-CLL1. Conclusions: Early-diagnosis CLL displays a biased IGHV repertoire with stereotyped configurations characteristic of CLL, including subsets that are rare in the normal B-cell repertoire. These findings support a central role for antigen-driven selection in shaping CLL evolution.
  • Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia
    Martina Cardillo, Fabiana Ferrero, Nadia Bertola, Ennio Nano, Rosanna Massara, Maria Cristina Capra, Daniele Reverberi, Monica Colombo, Vanessa Cossu, Fabio Ghiotto, Adalberto Ibatici, Emanuele Angelucci, Antonino Neri, Massimo Gentile, Fortunato Morabito, Andrea Nicola Mazzarello, Manlio Ferrarini, Franco Fais, Giovanna Cutrona
    International Journal of Molecular Sciences, 2026
    Chronic lymphocytic leukemia (CLL) is a dynamic malignancy in which intraclonal subfractions differ in activation history and responsiveness to microenvironmental signals. Here, we investigated the expression and inducibility of IL-12 family receptor subunits (IL-23R, IL-12Rβ1, IL-12Rβ2) and the related receptor complexes in recirculating CLL cells, with a focus on CXCR4/CD5-defined fractions: the proliferative fraction (PF; CXCR4dim/CD5bright; most recently divided, tissue-emigrated cells) and the resting fraction (RF; CXCR4bright/CD5dim; older, quiescent cells). At baseline, IL-12Rβ1 was enriched in the PF and was associated with a higher proportion of cells expressing IL-23R and IL-12R receptor complexes. Concomitantly, RT-qPCR disclosed higher IL-12Rβ1 mRNA levels. Following antigen-independent activation with CpG or CpG + IL-15, there was a marked increase in IL-23R and IL-12Rβ1 but not in IL-12Rβ2 surface expression, resulting in preferential upregulation of the IL-23R complex over the IL-12R complex. Fraction-specific analyses showed stronger induction of IL-23R and IL-23R complex expression in PF compared with RF. These findings identify an intraclonal bias toward IL-23 responsiveness in the CLL cells with a phenotype of recently divided, tissue-emigrated cells and suggest the IL-23/IL-23R axis as a potential therapeutic target.
  • To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy
    Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile
    European Journal of Haematology, 2026
    Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment. Over the past two decades, however, substantial advances in genomic profiling—including immunoglobulin heavy‐chain variable region (IGHV) mutational status, TP53 disruption, recurrent gene mutations, and complex karyotype—have uncovered marked biological heterogeneity among early‐stage patients and substantially improved prediction of disease progression. In parallel, targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors and venetoclax‐based combinations have transformed the management of symptomatic CLL, raising renewed interest in whether early intervention might favorably alter the natural history of biologically high‐risk disease. In this review, we critically examine the evolution of prognostication in early‐stage CLL, integrate contemporary molecular and clinical risk models, and summarize evidence from both historical chemotherapy‐era studies and modern early‐intervention trials. We discuss key unresolved controversies, including reliance on surrogate endpoints, the risks of overtreatment, and the persistent absence of an overall survival benefit across all early‐treatment strategies. Finally, we outline future research priorities, including refined genomic stratification, minimal residual disease‐driven (MRD)‐driven approaches, and combination targeted therapies currently under investigation. Despite renewed interest in preemptive treatment, available evidence supports continued observation for asymptomatic patients outside clinical trials.
  • Targeting the p53/xCT/GSH Axis with PRIMA-1Met Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia
    Martina Pasino, Andrea Speciale, Silvia Ravera, Giovanna Cutrona, Rosanna Massara, Nadia Bertola, Maurizio Viale, Irena Velkova, Andrea Nicola Mazzarello, Franco Fais, Fabrizio Loiacono, Serena Matis, Giulia Elda Valenti, Nicola Traverso, Cinzia Domenicotti, Barbara Marengo, Bruno Tasso, Adalberto Ibatici, Emanuele Angelucci, Tiziana Vaisitti, Paola Monti, Paola Menichini
    International Journal of Molecular Sciences, 2025
    In Chronic Lymphocytic Leukemia (CLL), mutations at the TP53 tumor suppressor gene are an important hallmark since they may strongly influence the therapeutic decision. PRIMA-1Met (also known as APR-246/Eprenetapopt) is a small molecule able to restore the wild-type (wt) p53 conformation to mutant p53 proteins and to stimulate apoptosis in tumor cells; in addition, it can deplete the glutathione reservoir, increasing reactive oxygen species (ROS) production. In this study, we investigated whether combining PRIMA-1Met with Sulfasalazine (SAS), a SLC7A11/xCT inhibitor, reduces CLL cell viability by targeting mutant p53 and the glutathione pathway. The results demonstrated that, in CLL cells, PRIMA-1Met did not restore the wt functions in the mutant p53 proteins, but it strongly reduced the antioxidant defense and induced cell death. PRIMA-1Met and SAS combination synergistically reduced cell survival regardless of p53 status and further impaired antioxidant capacity, especially in mutant p53 cells, linking their cytotoxic effect to redox imbalance. Thus, the association of PRIMA-1Met with drugs targeting the antioxidant response could represent a valid strategy to kill CLL cells carrying either wt or mutant p53.
  • MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study
    Ennio Nano, Francesco Reggiani, Adriana Agnese Amaro, Paola Monti, Monica Colombo, Nadia Bertola, Fabiana Ferrero, Franco Fais, Antonella Bruzzese, Enrica Antonia Martino, Ernesto Vigna, Noemi Puccio, Mariaelena Pistoni, Federica Torricelli, Graziella D’Arrigo, Gianluigi Greco, Giovanni Tripepi, Carlo Adornetto, Massimo Gentile, Manlio Ferrarini, Massimo Negrini, Fortunato Morabito, Antonino Neri, Giovanna Cutrona
    Non Coding RNA, 2024
    A “watch and wait” strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study, six well-established variables (i.e., Rai stage, beta-2-microglobulin levels, IGVH mutational status, del11q, del17p, and NOTCH1 mutations) maintained significant associations with TTFT in a basic multivariable model, collectively yielding a Harrell’s C-index of 75% and explaining 45.4% of the variance in the prediction of TTFT. Concerning miRNAs, 73 out of 513 were significantly associated with TTFT in a univariable model; of these, 16 retained an independent relationship with the outcome in a multivariable analysis. For 8 of these (i.e., miR-582-3p, miR-33a-3p, miR-516a-5p, miR-99a-5p, and miR-296-3p, miR-502-5p, miR-625-5p, and miR-29c-3p), a lower expression correlated with a shorter TTFT, whereas in the remaining eight (i.e., miR-150-5p, miR-148a-3p, miR-28-5p, miR-144-5p, miR-671-5p, miR-1-3p, miR-193a-3p, and miR-124-3p), the higher expression was associated with shorter TTFT. Integrating these miRNAs into the basic model significantly enhanced predictive accuracy, raising the Harrell’s C-index to 81.1% and the explained variation in TTFT to 63.3%. Moreover, the inclusion of the miRNA scores enhanced the integrated discrimination improvement (IDI) and the net reclassification index (NRI), underscoring the potential of miRNAs to refine CLL prognostic models and providing insights for clinical decision-making. In silico analyses on the differently expressed miRNAs revealed their potential regulatory functions of several pathways, including those involved in the therapeutic responses. To add a biological context to the clinical evidence, an miRNA–mRNA correlation analysis revealed at least one significant negative correlation between 15 of the identified miRNAs and a set of 50 artificial intelligence (AI)-selected genes, previously identified by us as relevant for TTFT prediction in the same cohort of CLL patients. In conclusion, the identification of specific miRNAs as predictors of TTFT holds promise for enhancing risk stratification in CLL to predict therapeutic needs. However, further validation studies and in-depth functional analyses are required to confirm the robustness of these observations and to facilitate their translation into meaningful clinical utility.
  • Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates
    Andrea N. Mazzarello, Elena Gugiatti, Vanessa Cossu, Nadia Bertola, Davide Bagnara, Sonia Carta, Silvia Ravera, Chiara Salvetti, Adalberto Ibatici, Fabio Ghiotto, Monica Colombo, Giovanna Cutrona, Cecilia Marini, Gianmario Sambuceti, Franco Fais, Silvia Bruno
    Cancer Immunology Immunotherapy, 2024
    Chronic lymphocytic leukemia (CLL) is a disease of the elderly, often presenting comorbidities like osteoporosis and requiring, in a relevant proportion of cases, treatment with bisphosphonates (BPs). This class of drugs was shown in preclinical investigations to also possess anticancer properties. We started an in vitro study of the effects of BPs on CLL B cells activated by microenvironment-mimicking stimuli and observed that, depending on drug concentration, hormetic effects were induced on the leukemic cells. Higher doses induced cytotoxicity whereas at lower concentrations, more likely occurring in vivo, the drugs generated a protective effect from spontaneous and chemotherapy-induced apoptosis, and augmented CLL B cell activation/proliferation. This CLL-activation effect promoted by the BPs was associated with markers of poor CLL prognosis and required the presence of bystander stromal cells. Functional experiments suggested that this phenomenon involves the release of soluble factors and is increased by cellular contact between stroma and CLL B cells. Since CLL patients often present comorbidities such as osteoporosis and considering the diverse outcomes in both CLL disease progression and CLL response to treatment among patients, illustrating this phenomenon holds potential significance in driving additional investigations.
  • Unraveling the Bone Tissue Microenvironment in Chronic Lymphocytic Leukemia
    Paolo Giannoni, Cecilia Marini, Giovanna Cutrona, Gian Mario Sambuceti, Franco Fais, Daniela de Totero
    Cancers, 2023
    Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western countries. Although characterized by the progressive expansion and accumulation of leukemic B cells in peripheral blood, CLL cells develop in protective niches mainly located within lymph nodes and bone marrow. Multiple interactions between CLL and microenvironmental cells may favor the expansion of a B cell clone, further driving immune cells toward an immunosuppressive phenotype. Here, we summarize the current understanding of bone tissue alterations in CLL patients, further addressing and suggesting how the multiple interactions between CLL cells and osteoblasts/osteoclasts can be involved in these processes. Recent findings proposing the disruption of the endosteal niche by the expansion of a leukemic B cell clone appear to be a novel field of research to be deeply investigated and potentially relevant to provide new therapeutic approaches.
  • The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia
    Fortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, Luca Laurenti, Gianluigi Reda, Riccardo Moia, Adalgisa Condoluci, Iolanda Vincelli, Annalisa Chiarenza, Ernesto Vigna, Enrica Antonia Martino, Antonella Bruzzese, Sabrina Mezzatesta, Roberta Laureana, Giovanna Cutrona, Francesco Di Raimondo, Gilberto Fronza, Antonella Zucchetto, Riccardo Bomben, Francesca Maria Rossi, Jacopo Olivieri, Francesco Zaja, Davide Rossi, Gianluca Gaidano, Maria Ilaria Del Principe, Fiorella Ilariucci, Giovanni Del Poeta, Manlio Ferrarini, Antonino Neri, Valter Gattei, Massimo Gentile
    American Journal of Hematology, 2023
    Approximately, 80% of chronic lymphocytic leukemia (CLL) patients are diagnosed in the asymptomatic phase and/or at an early stage of the disease. Although the majority of these patients show a low-risk profile and are managed with active observation,1 the time to the first treatment (TTFT) in these CLL patients appears quite heterogeneous. Historical clinical observations suggested that CLL patients experiencing early progression develop a persistent risk of short overall survival (OS).2 Similar findings indicating a correlation between early progression after therapy and short OS have been reported in other hematological malignancies.3-5 Here, we hypothesized that an early need for treatment could inform OS also in the CLL setting. Therefore, we investigated the inclusion of the duration of the therapy-free interval following diagnosis as additional prognosticator to refine the OS prediction of well-recognized risk factors in a wide multicenter cohort of newly diagnosed CLL patients on a watch-and-wait strategy. The REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria were followed throughout this study.6 Further details in Supplementary Appendix. Distribution in the whole cohort of 3860 CLL cases of the clinical and biological variables validated in CLL-IPI7 and Brno-Barcelona8 score systems, including age, Rai staging, β2-microglobulin, immunoglobulin heavy-chain variable (IGHV) gene mutational status, del(11q) and del(17p), all tested at diagnosis/first presentation, are reported in Supplementary Table 1. Distribution of variables is as expected in a cohort of early-stage CLL.9 Sufficient information for evaluation of the CLL-IPI7 and Brno-Barcelona8 score systems were available in 2573 cases, which were included in the final analysis (Supplementary Figure 1). The median follow-up time was 6.8 years (interquartile range: 4.2–9.9 years). At univariate analyses, age ≥65 years, Rai stages I–II, abnormal β2M serum levels, del(11q), IGHVunmut status and del(17p) were all OS predictors both in univariable and multivariable analysis; this basic model provided an explained variation in mortality (R2) and a Harrell's C index of 37.7% and 72.6%, respectively (Supplementary Table 2). Patients experiencing therapy need within 6, 12, 18, 24, 30, 36, 42, 48, 54, and 60 months from diagnosis were defined as TTFT6-60 failures (TTFT6-60Fail). Cases remaining therapy-free within 6–60 months were categorized as TTFT6-60 achievers (TTFT6-60Achieve). OS for TTFT6-60Fail cases was defined as the time from TTFT6-60 failure to death or last follow-up. OS for patients with TTFT6-60Achieve was defined as the survival time from achieving TTFT6-60 until death or last follow-up. In each TTFT6-60 category, patients died before 6–60 months or with <6–60 months of follow-up were excluded from the analysis (Supplementary Figure 1). Cases requiring therapy within 6–60 months (TTFT6-60Fail) experienced a roughly three-time higher risk of dying (Hazard ratios (HRs) ranging from 2.6 to 3.2) as compared to patients with a longer therapy-free interval (TTFT6-60Achieve; reference group, HR = 1) in univariate Cox analyses (Supplementary Table 3). All the investigated cut-offs of TTFT, except the TTFT6 (p = .083), independently predicted the mortality incidence rate (HR ranging from 1.45 to 2.04) in a sequence of multivariable models including all the variables of the CLL-IPI and the Brno-Barcelona scores as potential confounders (Supplementary Table 4). In addition, the inclusion of the biomarker TTFT in the range from TTFT12 to TTFT42 significantly improved the prognostic accuracy of this risk stratification model compared to a model including the CLL-IPI and Brno-Barcelona scores variables alone (Supplementary Table 2), as witnessed by higher values for both R2 and Harrell's indices (values ranging from 38.6% to 40.4%, and from 72.9% to 73.8%, respectively; Supplementary Table 4) in models that include TTFT values. Conversely, TTFT at time points ranging from 48 to 60 months failed to add prognostic accuracy to the same model in terms of R2 and Harrel's indices (Supplementary Table 4). Remarkably, the zenith of the prognostic accuracy of TTFT was found at a cut-off value of 18 months (TTFT18; HR 2.04, 95% CI 1.52–2.75; R2 40.4%; Harrell's C index 73.8%), while at values of TTFT ranging from 24 to 60 months, a gradual reduction of both R2 (from 39.8% to 36.3%) and Harrell's C index (from 73.3% to 70.9%) was observed (Supplementary Figure 2). To establish whether the prognostic power of TTFT18Fail was dependent not only on the time of the therapy (i.e., less than 18 months) but also on treatment (i.e., treated/untreated), we performed univariate and multivariable Cox analyses by splitting cases of our cohort in those never-treated (never-treated TTFT18Achieve) from those treated but after 18 months (TTFT18Achieve) and comparing them with TTFT18Fail cases. A significantly shorter OS was accounted for in cases with TTFT18Fail (median 8 years) compared with treated TTFT18Achieve (median 13 years) and with never-treated TTFT18Achieve cases (median 22 years; Supplementary Figure 3). In this context, however, when tested by multivariable analysis (n = 2336), the treated TTFT18Achieve group lost its independent prognostic role with respect to the never-treated TTFT18Achieve group, while TTFT18Fail remained an independent prognostic factor of OS together with del(17p), del(11q), abnormal β2M serum level, IGHVunmut status, and age, but not Rai stage (Supplementary Table 5; R2, 42%; C index, 75%). In an additional multivariable model utilizing the same variables but combining the treated and never-treated TTFT18Achieve groups in a single group, TTFT18 remained again independent predictor of OS along with β2M, del(11q), del(17p), IGHV gene status and age, while the Rai stage lost its prognostic value (Supplementary Table 6). According to this multivariable model, we derived a novel survival risk score (SRS), which included TTFT18 as a new prognostic factor (SRSTTFT18), which utilizes the regression coefficients in predicting mortality to assign weights to the various variables independently associated with death (Supplementary Table 6). After calculating the assigned risk scores on an individual basis, patients were first grouped into four risk categories by quartile (Supplementary Figure 4); then, since the second quartile did not significantly differ from the third quartile, the two curves were collapsed together (Figure 1). Based on such stratification, 622 (26.6%) cases of the cohort were allocated in the low-risk group, 930 (39.8%) in the intermediate-risk group, and 784 (33.6%) in the high-risk group (SRSTTFT18 0 = low risk; score >0–37.8 = intermediate risk; score > 37.8 = high risk; Supplementary Table 6). The 5-year probability was respectively 97.5% for low-risk group (HR = 1, reference category), 91.8% (HR = 3.2, 95% CI 2.2–4.7, p < .001) for intermediate-risk group, and 77.7% (HR = 10.3, 95% CI 7.2–14.7, p < 0.001) for high-risk group (Figure 1). Notably, differently from the low-risk group, which did not cross the median timeline, the estimated median OS was 16 years (95%CI 10.7–21.6 years) and 9.9 years (95%CI 8.1–10.1 years) for intermediate- and high-risk cases, respectively (Figure 1). The Harrell's C index and the explained variation in mortality were consistently higher for scores including TTFT18 than those excluding this variable (72.6% vs. 73.8% and 37.7% vs. 40.4% for HC and R2, respectively). The significant improvement in the goodness of fit (expanded vs. reduced model, χ2 = 22.14 [1 df], p < .001) indicated that the inclusion of TTFT18 into the reduced model significantly increased the prognostic accuracy of the same model for predicting mortality. Herein, we demonstrated for the first time the independent prognostic value on mortality of the duration of TTFT ranging from 12 to 60 months in a sizeable cohort of newly diagnosed CLL patients, initially followed by a watch-and-wait strategy. We showed that patients who experienced an early therapy need within 6–60 months (TTFT6-60Fail) experienced roughly three-time higher risk of dying than those with a longer therapy-free interval (TTFT6-60Achieve). When risk factors included in the CLL-IPI2 and Brno-Barcelona score systems3 were jointly introduced into the same multivariable model with several TTFT thresholds, cases experiencing therapy need within 12 through 60 months, i.e., those labeled as TTFT12-60Fail were independently associated with the worst outcome. Notably, the inclusion into the basic model of the time-to-therapy starts thresholds significantly increased the prognostic accuracy of the same risk model, achieving the best performance at the time-point of 18 months. Nevertheless, Harrell's C indices exceeded the 70% threshold in all the investigated TTFT intervals, underscoring the prognostic utility of the first therapy-free length in addition to the treatment itself. The clinical impact of TTFT18 on OS prompted us to design a novel scoring system incorporating this variable (SRSTTFT18) to predict mortality in CLL. Several measures of predictive performance were considered, all validating the SRSTTFT18. First, a significant improvement in fitness favoring the expanded model (with the TTFT18 variable) versus the reduced model (without the TTFT18 variable) was demonstrated. Second, Harrell's C index was higher for the model including TTFT18, although the accepted 70% threshold was exceeded in both cases. These data demonstrated that a risk prediction model that included TTFT18 had better prognostic accuracy than models without this new prognostic variable. Our SRSTTFT18 included both unchanging variables, that is, IGHV mutational status and TTFT18, along with a changing variable (age) and other variables that may change over time (i.e., β2M, 17p, and 11q deletions) thus ultimately modifying the initial risk class assignment. In this context, a reiterative model, similar to the CIRI score,10 that redefines the risk at different time points, including those of TTFT calculation, would be more meaningful for the patients. In conclusion, the results of this study may aid the identification of early-stage progressive cases who allegedly will fail from conventional therapies and can in turn benefit from risk-adapted treatment approaches with chemo-free regimens. However, this new prognosticator could be reconsidered in the setting of patients up-front treated with new drugs. Fortunato Morabito, Valter Gattei, and Massimo Gentile designed the study. Fortunato Morabito, Giovanni Tripepi, Massimo Gentile, Sabrina Mezzatesta, performed statistical analysis; Fortunato Morabito, Luca Laurenti, Gianluigi Reda, Iolanda Vincelli, Ernesto Vigna, Antonella Bruzzese, Antonella Zucchetto, Riccardo Bomben, Francesco Di Raimondo, Jacopo Olivieri, Giovanni Del Poeta, Massimo Gentile, Manlio Ferrarini, Giovanni Tripepi, Davide Rossi, Gianluca Gaidano, Enrica Antonia Martino, Gilberto Fronza, Adalgisa Condoluci, Giovanna Cutrona, Francesca Romana Mauro, Riccardo Moia, Francesco Di Raimondo, Fiorella Ilariucci, Antonino Neri, and Francesco Zaja analyzed and interpreted data. Fortunato Morabito, Massimo Gentile, Manlio Ferrarini, Antonino Neri, and Valter Gattei wrote the manuscript; all authors gave final approval with the only exclusion of Giovanni Del Poeta (deceased). Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5× 1000 n. 9980 (to Fortunato Morabito, Manlio Ferrarini, Antonino Neri); AIRC, Special Program Metastases (n. 21198) 5× 1000 to Gianluca Gaidano; AIRC IG-5506 (to Gilberto Fronza), IG-14326 (to Manlio Ferrarini), IG-21687 (to Valter Gattei); AIRC and Fondazione CaRiCal co-financed Multi-Unit Regional Grant 2014 no. 16695 to Fortunato Morabito; Progetto Ricerca Finalizzata Italian Ministry of Health, Rome, RF-2018-12 365 790 (to Antonella Zucchetto and Giovanna Cutrona) and PE-2016-02362756 (to Valter Gattei); Italy Compagnia S. Paolo, Turin, Italy, Project 2017.0526 (to Gilberto Fronza); partially funded by Italian Ministry of Health (Project 5× 1000, 2015 and 2016) and Current Research 2016 and 2023 (to Gilberto Fronza, Giovanna Cutrona, and Antonino Neri); Swiss Cancer League, ID 3746, 4395, 4660, and 4705, Bern, Switzerland; European Research Council (ERC) Consolidator Grant CLLCLONE, ID: 772051 (to Davide Rossi); Swiss National Science Foundation, ID 320030_169670/1 and 310030_192439, Berne, Switzerland; The Leukemia & Lymphoma Society, Translational Research Program, ID 6594-20, New York. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Supplementary appendix Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
  • Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
    Fortunato Morabito, Carlo Adornetto, Paola Monti, Adriana Amaro, Francesco Reggiani, Monica Colombo, Yissel Rodriguez-Aldana, Giovanni Tripepi, Graziella D’Arrigo, Claudia Vener, Federica Torricelli, Teresa Rossi, Antonino Neri, Manlio Ferrarini, Giovanna Cutrona, Massimo Gentile, Gianluigi Greco
    Frontiers in Oncology, 2023
    Analyzing gene expression profiles (GEP) through artificial intelligence provides meaningful insight into cancer disease. This study introduces DeepSHAP Autoencoder Filter for Genes Selection (DSAF-GS), a novel deep learning and explainable artificial intelligence-based approach for feature selection in genomics-scale data. DSAF-GS exploits the autoencoder’s reconstruction capabilities without changing the original feature space, enhancing the interpretation of the results. Explainable artificial intelligence is then used to select the informative genes for chronic lymphocytic leukemia prognosis of 217 cases from a GEP database comprising roughly 20,000 genes. The model for prognosis prediction achieved an accuracy of 86.4%, a sensitivity of 85.0%, and a specificity of 87.5%. According to the proposed approach, predictions were strongly influenced by CEACAM19 and PIGP, moderately influenced by MKL1 and GNE, and poorly influenced by other genes. The 10 most influential genes were selected for further analysis. Among them, FADD, FIBP, FIBP, GNE, IGF1R, MKL1, PIGP, and SLC39A6 were identified in the Reactome pathway database as involved in signal transduction, transcription, protein metabolism, immune system, cell cycle, and apoptosis. Moreover, according to the network model of the 3D protein-protein interaction (PPI) explored using the NetworkAnalyst tool, FADD, FIBP, IGF1R, QTRT1, GNE, SLC39A6, and MKL1 appear coupled into a complex network. Finally, all 10 selected genes showed a predictive power on time to first treatment (TTFT) in univariate analyses on a basic prognostic model including IGHV mutational status, del(11q) and del(17p), NOTCH1 mutations, β2-microglobulin, Rai stage, and B-lymphocytosis known to predict TTFT in CLL. However, only IGF1R [hazard ratio (HR) 1.41, 95% CI 1.08-1.84, P=0.013), COL28A1 (HR 0.32, 95% CI 0.10-0.97, P=0.045), and QTRT1 (HR 7.73, 95% CI 2.48-24.04, P&amp;lt;0.001) genes were significantly associated with TTFT in multivariable analyses when combined with the prognostic factors of the basic model, ultimately increasing the Harrell’s c-index and the explained variation to 78.6% (versus 76.5% of the basic prognostic model) and 52.6% (versus 42.2% of the basic prognostic model), respectively. Also, the goodness of model fit was enhanced (χ2 = 20.1, P=0.002), indicating its improved performance above the basic prognostic model. In conclusion, DSAF-GS identified a group of significant genes for CLL prognosis, suggesting future directions for bio-molecular research.
  • A High Percentage of CD16+ Monocytes Correlates with the Extent of Bone Erosion in Chronic Lymphocytic Leukemia Patients: The Impact of Leukemic B Cells in Monocyte Differentiation and Osteoclast Maturation
    Paolo Giannoni, Cecilia Marini, Giovanna Cutrona, Katia Todoerti, Antonino Neri, Adalberto Ibatici, Gianmario Sambuceti, Simona Pigozzi, Marco Mora, Manlio Ferrarini, Franco Fais, Daniela de Totero
    Cancers, 2022
    Significant skeletal alterations are present in Chronic Lymphocytic Leukemia (CLL) patients; bone erosion, particularly evident in the long bone shaft, appeared increased in the progressive disease stage. Moreover, the partial colonization of the bone with reactive bone marrow we documented via PET-FDG imaging suggests that neoplastic cell overgrowth contributes to bone derangement. Indeed, cytokines released by leukemic B cells impair osteoblast differentiation and enhance osteoclast formation in vitro. CD16, Fcγ-RIIIa, has been previously indicated as a marker of osteoclast precursors. We demonstrate, here, that the percentage of circulating monocytes, CD16+, is significantly higher in CLL patients than in normal controls and directly correlated with the extent of bone erosion. When we assessed if healthy monocytes, treated with a CLL-conditioned medium, modulated RANK, RANKL and CD16, we observed that all these molecules were up-regulated and CD16 to a greater extent. Altogether, these findings suggest that leukemic cells facilitate osteoclast differentiation. Interestingly, the evidence that monocytes, polarized toward the M2 phenotype, were characterized by high CD16 expression and showed a striking propensity to differentiate toward osteoclasts may provide further explanations for the enhanced levels of bone erosion detected, in agreement with the high number of immunosuppressive-M2 cells present in these patients.
  • The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study
    Giuseppa De Luca, Giannamaria Cerruti, Sonia Lastraioli, Romana Conte, Adalberto Ibatici, Nikki Di Felice, Fortunato Morabito, Paola Monti, Gilberto Fronza, Serena Matis, Monica Colombo, Sonia Fabris, Alessia Ciarrocchi, Antonino Neri, Paola Menichini, Manlio Ferrarini, Paolo Nozza, Franco Fais, Giovanna Cutrona, Mariella Dono
    Hematological Oncology, 2022
  • Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia
    Davide Bagnara, Andrea Nicola Mazzarello, Fabio Ghiotto, Monica Colombo, Giovanna Cutrona, Franco Fais, Manlio Ferrarini
    International Journal of Molecular Sciences, 2022
  • MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells
    Serena Matis, Anna Grazia Recchia, Monica Colombo, Martina Cardillo, Marina Fabbi, Katia Todoerti, Sabrina Bossio, Sonia Fabris, Valeria Cancila, Rosanna Massara, Daniele Reverberi, Laura Emionite, Michele Cilli, Giannamaria Cerruti, Sandra Salvi, Paola Bet, Simona Pigozzi, Roberto Fiocca, Adalberto Ibatici, Emanuele Angelucci, Massimo Gentile, Paola Monti, Paola Menichini, Gilberto Fronza, Federica Torricelli, Alessia Ciarrocchi, Antonino Neri, Franco Fais, Claudio Tripodo, Fortunato Morabito, Manlio Ferrarini, Giovanna Cutrona
    Blood Advances, 2022
  • Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements
    Davide Bagnara, Monica Colombo, Daniele Reverberi, Serena Matis, Rosanna Massara, Niccolò Cardente, Gianluca Ubezio, Vanessa Agostini, Luca Agnelli, Antonino Neri, Martina Cardillo, Stefano Vergani, Fabio Ghiotto, Andrea Nicola Mazzarello, Fortunato Morabito, Giovanna Cutrona, Manlio Ferrarini, Franco Fais
    Frontiers in Oncology, 2022
  • LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells
    Serena Matis, Martina Rossi, Lorenzo Brondolo, Martina Cardillo, Daniele Reverberi, Rosanna Massara, Monica Colombo, Adalberto Ibatici, Emanuele Angelucci, Tiziana Vaisitti, Silvia Bruno, Sonia Fabris, Antonino Neri, Massimo Gentile, Fortunato Morabito, Giovanna Cutrona, Paola Briata, Roberto Gherzi, Franco Fais
    Hematological Oncology, 2022
  • Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: Role of TNFα, IL-6 and IL-11 cytokines
    Paolo Giannoni, Cecilia Marini, Giovanna Cutrona, Serena Matis, Maria Cristina Capra, Francesca Puglisi, Paola Luzzi, Simona Pigozzi, Gabriele Gaggero, Antonino Neri, Katia Todoerti, Fortunato Morabito, Adalberto Ibatici, Maurizio Miglino, Micaela Bergamaschi, Silvia Bruno, Gian Mario Sambuceti, Jean Louis Ravetti, Manlio Ferrarini, Franco Fais, Daniela de Totero
    Haematologica, 2021
  • Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia
    Fortunato Morabito, Giovanni Tripepi, Riccardo Moia, Anna Grazia Recchia, Paola Boggione, Francesca Romana Mauro, Sabrina Bossio, Graziella D’Arrigo, Enrica Antonia Martino, Ernesto Vigna, Francesca Storino, Gilberto Fronza, Francesco Di Raimondo, Davide Rossi, Adalgisa Condoluci, Monica Colombo, Franco Fais, Sonia Fabris, Robin Foa, Giovanna Cutrona, Massimo Gentile, Emili Montserrat, Gianluca Gaidano, Manlio Ferrarini, Antonino Neri
    Frontiers in Oncology, 2021
  • Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials
    Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al‐Janazreh, Ernesto Vigna, Enrica Antonia Martino, Ramona Cassin, Graziella D′Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Paola Monti, Paola Menichini, Jacopo Olivieri, Giovanna Cutrona, Davide Rossi, Antonio Cuneo, Francesco Di Raimondo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile
    American Journal of Hematology, 2021
  • TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
    Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Anna Grazia Recchia, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al‐Janazreh, Enrica Antonia Martino, Ernesto Vigna, Giovanni Tripepi, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Ozren Jaksic, Jacopo Olivieri, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile
    American Journal of Hematology, 2021
  • Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol
    Fortunato Morabito, Giovanni Tripepi, Ernesto Vigna, Sabrina Bossio, Graziella D’Arrigo, Enrica Antonia Martino, Francesca Storino, Anna Grazia Recchia, Gilberto Fronza, Francesco Di Raimondo, Monica Colombo, Franco Fais, Antonino Neri, Giovanna Cutrona, Manlio Ferrarini, Massimo Gentile
    European Journal of Haematology, 2021
  • Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study
    Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Ernesto Vigna, Enrica Antonia Martino, Francesco Mendicino, Cirino Botta, Daniele Caracciolo, Ramona Cassin, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Giovanna Cutrona, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile
    American Journal of Hematology, 2021
  • Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases
    Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Sabrina Bossio, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Andrea Visentin, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al‐Janazreh, Ernesto Vigna, Enrica Antonia Martino, Francesco Mendicino, Ramona Cassin, Graziella D'Arrigo, Sara Galimberti, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Antonino Neri, Gilberto Fronza, Paola Monti, Paola Menichini, Giovanna Cutrona, Ozren Jaksic, Davide Rossi, Francesco Di Raimondo, Antonio Cuneo, Gianluca Gaidano, Aaron Polliack, Livio Trentin, Robin Foà, Manlio Ferrarini, Valter Gattei, Massimo Gentile
    European Journal of Haematology, 2021
  • Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients
    Jennifer C. Reid, Diana Golubeva, Allison L. Boyd, Cameron G. Hollands, Charisa Henly, Luca Orlando, Andrew Leber, Josée Hébert, Fortunato Morabito, Giovanna Cutrona, Luca Agnelli, Massimo Gentile, Manlio Ferrarini, Antonino Neri, Brian Leber, Mickie Bhatia
    Cell Reports, 2021
  • Spotlight on melphalan flufenamide: An up-and-coming therapy for the treatment of myeloma
    Fortunato Morabito, Giovanni Tripepi, Enrica Antonia Martino, Ernesto Vigna, Francesco Mendicino, Lucio Morabito, Katia Todoerti, Hamdi Al-Janazreh, Graziella D’Arrigo, Filippo Antonio Canale, Giovanna Cutrona, Antonino Neri, Massimo Martino, Massimo Gentile
    Drug Design Development and Therapy, 2021
  • Antitumor effects of PRIMA-1 and PRIMA-1met (APR246) in hematological malignancies: Still a mutant p53-dependent affair?
    Paola Menichini, Paola Monti, Andrea Speciale, Giovanna Cutrona, Serena Matis, Franco Fais, Elisa Taiana, Antonino Neri, Riccardo Bomben, Massimo Gentile, Valter Gattei, Manlio Ferrarini, Fortunato Morabito, Gilberto Fronza
    Cells, 2021
  • Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients
    Silvia Ravera, Fabio Ghiotto, Claudya Tenca, Elena Gugiatti, Sara Santamaria, Bernardetta Ledda, Adalberto Ibatici, Giovanna Cutrona, Andrea N. Mazzarello, Davide Bagnara, Martina Cardillo, Daniela Zarcone, Zbigniew Darzynkiewicz, Ermanno Ciccone, Franco Fais, Silvia Bruno
    Scientific Reports, 2020
  • Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients
    Paola Monti, Marta Lionetti, Giuseppa De Luca, Paola Menichini, Anna Grazia Recchia, Serena Matis, Monica Colombo, Sonia Fabris, Andrea Speciale, Marzia Barbieri, Massimo Gentile, Simonetta Zupo, Mariella Dono, Adalberto Ibatici, Antonino Neri, Manlio Ferrarini, Franco Fais, Gilberto Fronza, Giovanna Cutrona, Fortunato Morabito
    Scientific Reports, 2020
  • Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
    Paola Monti, Paola Menichini, Andrea Speciale, Giovanna Cutrona, Franco Fais, Elisa Taiana, Antonino Neri, Riccardo Bomben, Massimo Gentile, Valter Gattei, Manlio Ferrarini, Fortunato Morabito, Gilberto Fronza
    Frontiers in Oncology, 2020
  • Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
    Massimo Gentile, Enrica Antonia Martino, Andrea Visentin, Marta Coscia, Gianluigi Reda, Paolo Sportoletti, Francesca Romana Mauro, Luca Laurenti, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Ernesto Vigna, Francesco Mendicino, Eugenio Lucia, Sabrina Bossio, Anna Grazia Recchia, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Candida Vitale, Giovanni Tripepi, Graziella D’Arrigo, Ilaria Angeletti, Riccardo Bomben, Antonino Neri, Giovanna Cutrona, Gilberto Fronza, Francesco Di Raimondo, Gianluca Gaidano, Antonio Cuneo, Robin Foà, Manlio Ferrarini, Livio Trentin, Valter Gattei, Fortunato Morabito
    Blood Cancer Journal, 2020
  • TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors
    Fortunato Morabito, Massimo Gentile, Paola Monti, Anna Grazia Recchia, Paola Menichini, Mamdouh Skafi, Moien Atrash, Giuseppa De Luca, Sabrina Bossio, Hamdi Al-Janazreh, Sara Galimberti, Zaidoun Salah, Lucio Morabito, Alham Mujahed, Musa Hindiyeh, Mariella Dono, Franco Fais, Giovanna Cutrona, Antonino Neri, Giovanni Tripepi, Gilberto Fronza, Manlio Ferrarini
    Expert Opinion on Investigational Drugs, 2020
  • Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients
    Marta Lionetti, Marzia Barbieri, Vanessa Favasuli, Elisa Taiana, Sonia Fabris, Chiara Favoino, Gabriella Ciceri, Serena Matis, Monica Colombo, Rosanna Massara, Gianluigi Reda, Massimo Gentile, Valeria Spina, Davide Rossi, Luca Baldini, Gianluca Gaidano, Franco Fais, Manlio Ferrarini, Fortunato Morabito, Giovanna Cutrona, Antonino Neri
    Hematological Oncology, 2020
  • Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations
    Sara Raponi, Caterina Ilari, Irene Della Starza, Luca V. Cappelli, Luciana Cafforio, Alfonso Piciocchi, Valentina Arena, Paola Mariglia, Francesca R. Mauro, Massimo Gentile, Giovanna Cutrona, Riccardo Moia, Chiara Favini, Fortunato Morabito, Davide Rossi, Gianluca Gaidano, Anna Guarini, Ilaria Del Giudice, Robin Foà
    British Journal of Haematology, 2020
  • A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
    Jared A. Cohen, Francesca Maria Rossi, Antonella Zucchetto, Riccardo Bomben, Lodovico Terzi-di-Bergamo, Kari G. Rabe, Massimo Degan, Agostino Steffan, Jerry Polesel, Enrico Santinelli, Idanna Innocenti, Giovanna Cutrona, Giovanni D’Arena, Gabriele Pozzato, Francesco Zaja, Annalisa Chiarenza, Davide Rossi, Francesco Di Raimondo, Luca Laurenti, Massimo Gentile, Fortunato Morabito, Antonino Neri, Manlio Ferrarini, Christopher D. Fegan, Christopher J. Pepper, Giovanni Del Poeta, Sameer A. Parikh, Neil E. Kay, Valter Gattei
    Haematologica, 2020
  • International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
    Adalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, Manuela A. Hoechstetter, Carmen D. Herling, Lorenzo De Paoli, Julio Delgado, Kari G. Rabe, Massimo Gentile, Michael Doubek, Francesca R. Mauro, Giorgia Chiodin, Mattias Mattsson, Jasmin Bahlo, Giovanna Cutrona, Jana Kotaskova, Clara Deambrogi, Karin E. Smedby, Valeria Spina, Alessio Bruscaggin, Wei Wu, Riccardo Moia, Elena Bianchi, Bernhard Gerber, Emanuele Zucca, Silke Gillessen, Michele Ghielmini, Franco Cavalli, Georg Stussi, Mark A. Hess, Tycho S. Baumann, Antonino Neri, Manlio Ferrarini, Richard Rosenquist, Francesco Forconi, Robin Foà, Sarka Pospisilova, Fortunato Morabito, Stephan Stilgenbauer, Hartmut Döhner, Sameer A. Parikh, William G. Wierda, Emili Montserrat, Gianluca Gaidano, Michael Hallek, Davide Rossi
    Blood, 2020
  • Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach
    Monica Colombo, Davide Bagnara, Daniele Reverberi, Serena Matis, Martina Cardillo, Rosanna Massara, Luca Mastracci, Jean Louis Ravetti, Luca Agnelli, Antonino Neri, Michela Mazzocco, Margherita Squillario, Andrea Nicola Mazzarello, Giovanna Cutrona, Andreas Agathangelidis, Kostas Stamatopoulos, Manlio Ferrarini, Franco Fais
    Molecular Medicine, 2020
  • An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma
    Fortunato Morabito, Anna Grazia Recchia, Ernesto Vigna, Cirino Botta, Mamdouh Skafi, Mohammed Abu-Rayyan, Moien Atrash, Sara Galimberti, Lucio Morabito, Hamdi Al-Janazreh, Massimo Martino, Giovanna Cutrona, Massimo Gentile
    Expert Opinion on Pharmacotherapy, 2020
  • NEAT1 long isoform is highly expressed in chronic lymphocytic leukemia irrespectively of cytogenetic groups or clinical outcome
    Domenica Ronchetti, Vanessa Favasuli, Paola Monti, Giovanna Cutrona, Sonia Fabris, Ilaria Silvestris, Luca Agnelli, Monica Colombo, Paola Menichini, Serena Matis, Massimo Gentile, Ramil Nurtdinov, Roderic Guigó, Luca Baldini, Gilberto Fronza, Manlio Ferrarini, Fortunato Morabito, Antonino Neri, Elisa Taiana
    Non Coding RNA, 2020
  • Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing
    Luca Agnelli, Andrea Bisognin, Katia Todoerti, Martina Manzoni, Elisa Taiana, Serena Galletti, Giovanna Cutrona, Enrico Gaffo, Stefania Bortoluzzi, Antonino Neri
    Blood Cancer Journal, 2019
  • Hepatocyte growth factor: A microenvironmental resource for leukemic cell growth
    Paolo Giannoni, Franco Fais, Giovanna Cutrona, Daniela Totero
    International Journal of Molecular Sciences, 2019
  • Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
    Massimo Gentile, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Luca Laurenti, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela Rago, Osnat Bairey, Giovanni Tripepi, Kari G. Chaffee, Parikh A. Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Idanna Innocenti, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E. Kay, Aaron Polliack, Robin Foà, Fortunato Morabito
    European Journal of Haematology, 2018
  • A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells
    Elena Gugiatti, Claudya Tenca, Silvia Ravera, Marina Fabbi, Fabio Ghiotto, Andrea N. Mazzarello, Davide Bagnara, Daniele Reverberi, Daniela Zarcone, Giovanna Cutrona, Adalberto Ibatici, Ermanno Ciccone, Zbigniew Darzynkiewicz, Franco Fais, Silvia Bruno
    Haematologica, 2018
  • Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases
    Fortunato Morabito, Tait D Shanafelt, Massimo Gentile, Gianluigi Reda, Francesca Romana Mauro, Davide Rossi, Nicola Di Renzo, Stefano Molica, Francesco Angrilli, Annalisa Chiarenza, Giovanna Cutrona, Kari G. Chaffee, Sameer A. Parikh, Giovanni Tripepi, Graziella D'Arrigo, Ernesto Vigna, Anna Grazia Recchia, Agostino Cortelezzi, Gianluca Gaidano, Francesco Di Raimondo, Franco Fais, Robin Foà, Antonino Neri, Manlio Ferrarini
    American Journal of Hematology, 2018
  • Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
    Massimo Gentile, Tait D. Shanafelt, Gianluigi Reda, Francesca Romana Mauro, Katja Zirlik, Stefania Ciolli, Luca Laurenti, Maria Ilaria Del Principe, Davide Rossi, Nicola Di Renzo, Stefano Molica, Francesco Angrilli, Marta Coscia, Annalisa Chiarenza, Annamaria Giordano, Giovanna Cutrona, Kari G. Chaffee, Sameer A. Parikh, Giuseppina Uccello, Idanna Innocenti, Giovanni Tripepi, Graziella D’Arrigo, Ernesto Vigna, Anna Grazia Recchia, Yair Herishanu, Lev Shvidel, Tamar Tadmor, Agostino Cortelezzi, Giovanni Del Poeta, Gianluca Gaidano, Francesco Di Raimondo, Antonino Neri, Manlio Ferrarini, Robin Foà, Aaron Polliack, Fortunato Morabito
    Leukemia, 2018
  • Microenvironmental regulation of the IL-23R/IL-23 axis overrides chronic lymphocytic leukemia indolence
    Giovanna Cutrona, Claudio Tripodo, Serena Matis, Anna Grazia Recchia, Carlotta Massucco, Marina Fabbi, Monica Colombo, Laura Emionite, Sabina Sangaletti, Alessandro Gulino, Daniele Reverberi, Rosanna Massara, Simona Boccardo, Daniela de Totero, Sandra Salvi, Michele Cilli, Mariavaleria Pellicanò, Martina Manzoni, Sonia Fabris, Irma Airoldi, Francesca Valdora, Silvano Ferrini, Massimo Gentile, Ernesto Vigna, Sabrina Bossio, Laura De Stefano, Angela Palummo, Giovanni Iaquinta, Martina Cardillo, Simonetta Zupo, Giannamaria Cerruti, Adalberto Ibatici, Antonino Neri, Franco Fais, Manlio Ferrarini, Fortunato Morabito
    Science Translational Medicine, 2018
  • Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases
    Massimo Gentile, Tait D. Shanafelt, Francesca R. Mauro, Luca Laurenti, Davide Rossi, Stefano Molica, Iolanda Vincelli, Giovanna Cutrona, Giuseppina Uccello, Sara Pepe, Ernesto Vigna, Giovanni Tripepi, Kari G. Chaffee, Sameer A. Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito
    American Journal of Hematology, 2018
  • Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: A Possible Role for RANK/RANKL Pathway
    Cecilia Marini, Silvia Bruno, Francesco Fiz, Cristina Campi, Roberta Piva, Giovanna Cutrona, Serena Matis, Alberto Nieri, Maurizio Miglino, Adalberto Ibatici, Anna Maria Orengo, Anna Maria Massone, Carlo Emanuele Neumaier, Daniela de Totero, Paolo Giannoni, Matteo Bauckneht, Michele Pennone, Claudya Tenca, Elena Gugiatti, Alessandro Bellini, Anna Borra, Elisabetta Tedone, Hülya Efetürk, Francesca Rosa, Laura Emionite, Michele Cilli, Davide Bagnara, Valerio Brucato, Paolo Bruzzi, Michele Piana, Franco Fais, Gianmario Sambuceti
    Scientific Reports, 2017
  • Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells
    Eleonora Fonte, Maria Giovanna Vilia, Daniele Reverberi, Ilenia Sana, Lydia Scarfò, Pamela Ranghetti, Ugo Orfanelli, Simone Cenci, Giovanna Cutrona, Paolo Ghia, Marta Muzio
    Haematologica, 2017
  • Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy
    G Cutrona, S Matis, M Colombo, C Massucco, G Baio, F Valdora, L Emionite, S Fabris, A G Recchia, M Gentile, C E Neumaier, D Reverberi, R Massara, S Boccardo, L Basso, S Salvi, F Rosa, M Cilli, S Zupo, M Truini, P Tassone, M Calabrese, M Negrini, A Neri, F Morabito, F Fais, M Ferrarini
    Leukemia, 2017
  • Survival and immunosuppression induced by hepatocyte growth factor in chronic lymphocytic leukemia
    P. Giannoni, G. Cutrona, D. de Totero
    Current Molecular Medicine, 2017
  • Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression
    G Barisione, M Fabbi, G Cutrona, L De Cecco, S Zupo, B Leitinger, M Gentile, M Manzoni, A Neri, F Morabito, M Ferrarini, S Ferrini
    Blood Cancer Journal, 2017
  • The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients
    Stefano Molica, Tait D. Shanafelt, Diana Giannarelli, Massimo Gentile, Rosanna Mirabelli, Giovanna Cutrona, Luciano Levato, Nicola Di Renzo, Francesco Di Raimondo, Caterina Musolino, Francesco Angrilli, Angelo Famà, Anna Grazia Recchia, Kari G. Chaffee, Antonino Neri, Neil E. Kay, Manlio Ferrarini, Fortunato Morabito
    American Journal of Hematology, 2016
  • A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI)
    Francesca Valdora, Giovanna Cutrona, Serena Matis, Fortunato Morabito, Carlotta Massucco, Laura Emionite, Simona Boccardo, Luca Basso, Anna Grazia Recchia, Sandra Salvi, Francesca Rosa, Massimo Gentile, Marco Ravina, Daniele Pace, Angela Castronovo, Michele Cilli, Mauro Truini, Massimo Calabrese, Antonino Neri, Carlo Emanuele Neumaier, Franco Fais, Gabriella Baio, Manlio Ferrarini
    Clinical Immunology, 2016
  • Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients
    Massimo Gentile, Tait D. Shanafelt, Davide Rossi, Luca Laurenti, Francesca R. Mauro, Stefano Molica, Giovanna Cutrona, Giuseppina Uccello, Melissa Campanelli, Ernesto Vigna, Giovanni Tripepi, Kari G. Chaffee, Sameer A. Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito
    Blood, 2016
  • A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients
    M Gentile, T D Shanafelt, G Cutrona, S Molica, G Tripepi, I Alvarez, F R Mauro, N Di Renzo, F Di Raimondo, I Vincelli, K Todoerti, S Matis, C Musolino, S Fabris, E Vigna, L Levato, S Zupo, F Angrilli, U Consoli, G Festini, G Longo, A Cortelezzi, A Arcari, M Federico, D Mannina, A G Recchia, A Neri, N E Kay, M Ferrarini, F Morabito
    Leukemia, 2016
  • LncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome
    D Ronchetti, M Manzoni, L Agnelli, C Vinci, S Fabris, G Cutrona, S Matis, M Colombo, S Galletti, E Taiana, A G Recchia, S Bossio, M Gentile, C Musolino, F Di Raimondo, A Grilli, S Bicciato, A Cortelezzi, P Tassone, F Morabito, M Ferrarini, A Neri
    Blood Cancer Journal, 2016
  • Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study
    Massimo Gentile, Giovanna Cutrona, Stefano Molica, Fiorella Ilariucci, Francesca R. Mauro, Nicola Di Renzo, Francesco Di Raimondo, Iolanda Vincelli, Katia Todoerti, Serena Matis, Caterina Musolino, Sonia Fabris, Marta Lionetti, Luciano Levato, Simona Zupo, Francesco Angrilli, Ugo Consoli, Gianluca Festini, Giuseppe Longo, Agostino Cortelezzi, Pellegrino Musto, Massimo Federico, Antonino Neri, Manlio Ferrarini, Fortunato Morabito
    European Journal of Haematology, 2016
  • A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes
    Brian A. McCarthy, Sophia Yancopoulos, Mike Tipping, Xiao-jie Yan, Xue Ping Wang, Fiona Bennett, Wentian Li, Martin Lesser, Santanu Paul, Erin Boyle, Carolina Moreno, Rosa Catera, Bradley T. Messmer, Giovanna Cutrona, Manlio Ferrarini, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Andrew C. Rawstron, Nicholas Chiorazzi
    Immunologic Research, 2015
  • Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia
    Francesco Maura, Giovanna Cutrona, Laura Mosca, Serena Matis, Marta Lionetti, Sonia Fabris, Luca Agnelli, Monica Colombo, Carlotta Massucco, Manuela Ferracin, Barbara Zagatti, Daniele Reverberi, Massimo Gentile, Anna Grazia Recchia, Sabrina Bossio, Davide Rossi, Gianluca Gaidano, Stefano Molica, Agostino Cortelezzi, Francesco Di Raimondo, Massimo Negrini, Pierfrancesco Tassone, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    Leukemia and Lymphoma, 2015
  • Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation
    E. Fonte, A. Agathangelidis, D. Reverberi, S. Ntoufa, L. Scarfo, P. Ranghetti, G. Cutrona, A. Tedeschi, A. Xochelli, F. Caligaris-Cappio, M. Ponzoni, C. Belessi, Z. Davis, M. A. Piris, D. Oscier, P. Ghia, K. Stamatopoulos, M. Muzio
    Haematologica, 2015
  • Interleukin 21 controls mRNAand MicroRNA expression in CD40-activated chronic lymphocytic leukemia cells
    Loris De Cecco, Matteo Capaia, Simona Zupo, Giovanna Cutrona, Serena Matis, Antonella Brizzolara, Anna Maria Orengo, Michela Croce, Edoardo Marchesi, Manlio Ferrarini, Silvana Canevari, Silvano Ferrini
    Plos One, 2015
  • Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment
    Fortunato Morabito, Giovanna Cutrona, Laura Mosca, Marianna D’Anca, Serena Matis, Massimo Gentile, Ernesto Vigna, Monica Colombo, Anna Grazia Recchia, Sabrina Bossio, Laura De Stefano, Francesco Maura, Martina Manzoni, Fiorella Ilariucci, Ugo Consoli, Iolanda Vincelli, Caterina Musolino, Agostino Cortelezzi, Stefano Molica, Manlio Ferrarini, Antonino Neri
    Leukemia Research, 2015
  • Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia
    Francesco Maura, Laura Mosca, Sonia Fabris, Giovanna Cutrona, Serena Matis, Marta Lionetti, Luca Agnelli, Marzia Barbieri, Marianna D’Anca, Martina Manzoni, Monica Colombo, Carlotta Massucco, Daniele Reverberi, Massimo Gentile, Anna Grazia Recchia, Sabrina Bossio, Fiorella Ilariucci, Caterina Musolino, Francesco Di Raimondo, Agostino Cortelezzi, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    Plos One, 2015
  • Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study
    Fortunato Morabito, Giovanna Cutrona, Massimo Gentile, Sonia Fabris, Serena Matis, Ernesto Vigna, Katia Todoerti, Monica Colombo, Anna G. Recchia, Sabrina Bossio, Laura De Stefano, Fiorella Ilariucci, Agostino Cortelezzi, Ugo Consoli, Iolanda Vincelli, Emanuela A. Pesce, Caterina Musolino, Stefano Molica, Francesco Di Raimondo, Antonino Neri, Manlio Ferrarini
    British Journal of Haematology, 2015
  • MicroRNAome expression in chronic lymphocytic leukemia: Comparison with normal B-cell subsets and correlations with prognostic and clinical parameters
    Massimo Negrini, Giovanna Cutrona, Cristian Bassi, Sonia Fabris, Barbara Zagatti, Monica Colombo, Manuela Ferracin, Lucilla D'Abundo, Elena Saccenti, Serena Matis, Marta Lionetti, Luca Agnelli, Massimo Gentile, Anna Grazia Recchia, Sabrina Bossio, Daniele Reverberi, Gianmatteo Rigolin, George A. Calin, Silvia Sabbioni, Giandomenico Russo, Pierfrancesco Tassone, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    Clinical Cancer Research, 2014
  • Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages
    P. Giannoni, G. Pietra, G. Travaini, R. Quarto, G. Shyti, R. Benelli, L. Ottaggio, M. C. Mingari, S. Zupo, G. Cutrona, I. Pierri, E. Balleari, A. Pattarozzi, M. Calvaruso, C. Tripodo, M. Ferrarini, D. de Totero
    Haematologica, 2014
  • Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia
    Domenica Ronchetti, Giacomo Tuana, Andrea Rinaldi, Luca Agnelli, Giovanna Cutrona, Laura Mosca, Sonia Fabris, Serena Matis, Monica Colombo, Massimo Gentile, Anna Grazia Recchia, Ivo Kwee, Francesco Bertoni, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    Genes Chromosomes and Cancer, 2014
  • Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia
    Mirjam Hoxha, Sonia Fabris, Luca Agnelli, Valentina Bollati, Giovanna Cutrona, Serena Matis, Anna Grazia Recchia, Massimo Gentile, Agostino Cortelezzi, Fortunato Morabito, Pier Alberto Bertazzi, Manlio Ferrarini, Antonino Neri
    Genes Chromosomes and Cancer, 2014
  • Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study
    Massimo Gentile, Giovanna Cutrona, Laura Mosca, Serena Matis, Sonia Fabris, Marta Lionetti, Fiorella Ilariucci, Simona Zupo, Caterina Musolino, Luciano Levato, Stefano Molica, Francesco Di Raimondo, Iolanda Vincelli, Nicola Di Rienzo, Emanuela Anna Pesce, Francesco Angrilli, Massimo Federico, Antonino Neri, Manlio Ferrarini, Fortunato Morabito
    American Journal of Hematology, 2014
  • High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: Biological and clinical implications
    Marta Lionetti, Sonia Fabris, Giovanna Cutrona, Luca Agnelli, Carmela Ciardullo, Serena Matis, Gabriella Ciceri, Monica Colombo, Francesco Maura, Laura Mosca, Massimo Gentile, Anna G. Recchia, Fiorella Ilariucci, Caterina Musolino, Stefano Molica, Francesco Di Raimondo, Agostino Cortelezzi, Davide Rossi, Gianluca Gaidano, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    British Journal of Haematology, 2014
  • Clinical monoclonal B lymphocytosis versus rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features
    Fortunato Morabito, Laura Mosca, Giovanna Cutrona, Luca Agnelli, Giacomo Tuana, Manuela Ferracin, Barbara Zagatti, Marta Lionetti, Sonia Fabris, Francesco Maura, Serena Matis, Massimo Gentile, Ernesto Vigna, Monica Colombo, Carlotta Massucco, Anna Grazia Recchia, Sabrina Bossio, Laura De Stefano, Fiorella Ilariucci, Caterina Musolino, Stefano Molica, Francesco Di Raimondo, Agostino Cortelezzi, Pierfrancesco Tassone, Massimo Negrini, Sara Monti, Davide Rossi, Gianluca Gaidano, Manlio Ferrarini, Antonino Neri
    Clinical Cancer Research, 2013
  • Expression of immunoglobulin receptors with distinctive features indicating antigen selection by marginal zone B cells from human spleen
    Monica Colombo, Giovanna Cutrona, Daniele Reverberi, Silvia Bruno, Fabio Ghiotto, Claudya Tenca, Kostas Stamatopoulos, Anastasia Hadzidimitriou, Jenny Ceccarelli, Sandra Salvi, Simona Boccardo, Maria Grazia Calevo, Amleto De Santanna, Mauro Truini, Franco Fais, Manlio Ferrarini
    Molecular Medicine, 2013
  • Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia
    Domenica Ronchetti, Laura Mosca, Giovanna Cutrona, Giacomo Tuana, Massimo Gentile, Sonia Fabris, Luca Agnelli, Gabriella Ciceri, Serena Matis, Carlotta Massucco, Monica Colombo, Daniele Reverberi, Anna Grazia Recchia, Sabrina Bossio, Massimo Negrini, Pierfrancesco Tassone, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    BMC Medical Genomics, 2013
  • The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis
    Stefano Molica, Diana Giannarelli, Massimo Gentile, Giovanna Cutrona, Nicola Di Renzo, Francesco Di Raimondo, Antonino Neri, Massimo Federico, Manlio Ferrarini, Fortunato Morabito
    Leukemia Research, 2013
  • Total body computed tomography scan in the initial work-up of Binet stage a chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study
    Massimo Gentile, Giovanna Cutrona, Sonia Fabris, Emanuela Anna Pesce, Luca Baldini, Francesco Di Raimondo, Caterina Musolino, Paolo Di Tonno, Nicola Di Renzo, Stefano Molica, Maura Brugiatelli, Fiorella Ilariucci, Simona Zupo, Serena Matis, Francesco Maura, Ernesto Vigna, Francesco Angrilli, Anna Grazia Recchia, Giovanni Quarta, Emilio Iannitto, Alberto Fragasso, Pellegrino Musto, Mauro Spriano, Iolanda Vincelli, Daniele Vallisa, Agostino Cortelezzi, Francesca Romana Mauro, Robin Foà, Massimo Federico, Antonino Neri, Manlio Ferrarini, Fortunato Morabito
    American Journal of Hematology, 2013
  • Igs expressed by chronic lymphocytic leukemia B cells show limited binding-site structure variability
    Paolo Marcatili, Fabio Ghiotto, Claudya Tenca, Anna Chailyan, Andrea N Mazzarello, Xiao-Jie Yan, Monica Colombo, Emilia Albesiano, Davide Bagnara, Giovanna Cutrona, Fortunato Morabito, Silvia Bruno, Manlio Ferrarini, Nicholas Chiorazzi, Anna Tramontano, Franco Fais
    Journal of Immunology, 2013
  • External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia
    Stefano Molica, Diana Giannarelli, Massimo Gentile, Giovanna Cutrona, Nicola Di Renzo, Francesco Di Raimondo, Antonino Neri, Massimo Federico, Manlio Ferrrarini, Fortunato Morabito
    Cancer, 2013
  • Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia
    Sonia Fabris, Laura Mosca, Giovanna Cutrona, Marta Lionetti, Luca Agnelli, Gabriella Ciceri, Marzia Barbieri, Francesco Maura, Serena Matis, Monica Colombo, Massimo Gentile, Anna Grazia Recchia, Emanuela Anna Pesce, Francesco Di Raimondo, Caterina Musolino, Marco Gobbi, Nicola Di Renzo, Francesca Romana Mauro, Maura Brugiatelli, Fiorella Ilariucci, Maria Grazia Lipari, Francesco Angrilli, Ugo Consoli, Alberto Fragasso, Stefano Molica, Gianluca Festini, Iolanda Vincelli, Agostino Cortelezzi, Massimo Federico, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    American Journal of Hematology, 2013
  • The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia
    Fortunato Morabito, Rosaria De Filippi, Luca Laurenti, Katja Zirlik, Anna Grazia Recchia, Massimo Gentile, Emanuela Morelli, Ernesto Vigna, Vincenzo Gigliotti, Rosa Calemma, Barbara Amoroso, Antonino Neri, Giovanna Cutrona, Manlio Ferrarini, Stefano Molica, Giovanni Del Poeta, Claudio Tripodo, Antonio Pinto
    Blood, 2011
  • Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells
    Fabio Ghiotto, Paolo Marcatili, Claudya Tenca, Maria Grazia Calevo, Xiao-Jie Yan, Emilia Albesiano, Davide Bagnara, Monica Colombo, Giovanna Cutrona, Charles C. Chu, Fortunato Morabito, Silvia Bruno, Manlio Ferrarini, Anna Tramontano, Franco Fais, Nicholas Chiorazzi
    Molecular Medicine, 2011
  • CD38 and chronic lymphocytic leukemia: A decade later
    Fabio Malavasi, Silvia Deaglio, Rajendra Damle, Giovanna Cutrona, Manlio Ferrarini, Nicholas Chiorazzi
    Blood, 2011
  • Relevance of stereotyped b-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia
    Francesco Maura, Giovanna Cutrona, Sonia Fabris, Monica Colombo, Giacomo Tuana, Luca Agnelli, Serena Matis, Marta Lionetti, Massimo Gentile, Anna Grazia Recchia, Francesco Di Raimondo, Caterina Musolino, Fiorella Ilariucci, Nicola Di Renzo, Emanuela Pesce, Stefano Molica, Massimo Federico, Agostino Cortelezzi, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    Plos One, 2011
  • Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia
    Monica Colombo, Giovanna Cutrona, Daniele Reverberi, Sonia Fabris, Antonino Neri, Marina Fabbi, Giovanni Quintana, Giovanni Quarta, Fabio Ghiotto, Franco Fais, Manlio Ferrarini
    Molecular Medicine, 2011
  • Epigenetic mechanisms regulate ΔNP73 promoter function in human tonsil B cells
    Claudio Brigati, Barbara Banelli, Ida Casciano, Angela Di Vinci, Serena Matis, Giovanna Cutrona, Alessandra Forlani, Giorgio Allemanni, Massimo Romani
    Molecular Immunology, 2011
  • Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: A comparative study
    Sonia Fabris, Oronzo Scarciolla, Fortunato Morabito, Rosa Anna Cifarelli, Caterina Dininno, Giovanna Cutrona, Serena Matis, Anna Grazia Recchia, Massimo Gentile, Gabriella Ciceri, Manlio Ferrarini, Angela Ciancio, Clara Mannarella, Antonino Neri, Alberto Fragasso
    Genes Chromosomes and Cancer, 2011
  • Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia
    Sonia Fabris, Valentina Bollati, Luca Agnelli, Fortunato Morabito, Valeria Motta, Giovanna Cutrona, Serena Matis, Anna Grazia Recchia, Vincenzo Gigliotti, Massimo Gentile, Giorgio Lambertenghi Deliliers, Pier Alberto Bertazzi, Manlio Ferrarini, Antonino Neri, Andrea Baccarelli
    Epigenetics, 2011
  • More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia
    Fortunato Morabito, Giovanna Cutrona, Massimo Gentile, Fabrizio Loiacono, Serena Matis, Anna Grazia Recchia, Vincenzo Gigliotti, Vincenzo Callea, Simonetta Zupo, Manlio Ferrarini
    Leukemia Research, 2010
  • Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion
    Laura Mosca, Sonia Fabris, Marta Lionetti, Katia Todoerti, Luca Agnelli, Fortunato Morabito, Giovanna Cutrona, Adrian Andronache, Serena Matis, Francesco Ferrari, Massimo Gentile, Mauro Spriano, Vincenzo Callea, Gianluca Festini, Stefano Molica, Giorgio Lambertenghi Deliliers, Silvio Bicciato, Manlio Ferrarini, Antonino Neri
    Clinical Cancer Research, 2010
  • Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia
    Stefano Molica, Giovanna Digiesi, Caterina Battaglia, Giovanna Cutrona, Anna Antenucci, Matteo Molica, Diana Giannarelli, Isabella Sperduti, Massimo Gentile, Fortunato Morabito, Manlio Ferrarini
    European Journal of Haematology, 2010
  • Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience
    Stefano Molica, Francesco Di Raimondo, Giovanna Cutrona, Sonia Fabris, Francesca Mauro, Maura Brugiatelli, Luca Baldini, Pellegrino Musto, Stefano Sacchi, Agostino Cortelezzi, Robert Foà, Antonino Neri, Massimo Federico, Manlio Ferrarini, Fortunato Morabito
    Leukemia Research, 2010
  • Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells
    Daniela de Totero, Matteo Capaia, Marina Fabbi, Michela Croce, Raffaella Meazza, Giovanna Cutrona, Simona Zupo, Fabrizio Loiacono, Mauro Truini, Manlio Ferrarini
    Experimental Hematology, 2010
  • Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL
    Fortunato Morabito, Giovanna Cutrona, Massimo Gentile, Marina Fabbi, Serena Matis, Monica Colombo, Daniele Reverberi, Mauro Megna, Mauro Spriano, Vincenzo Callea, Ernesto Vigna, Edoardo Rossi, Eugenio Lucia, Gianluca Festini, Simonetta Zupo, Stefano Molica, Antonino Neri, Manlio Ferrarini
    British Journal of Haematology, 2010
  • PNAE can significantly reduce Burkitt's lymphoma tumor burden in a SCID mice model: Cells dissemination similar to the human disease
    S Matis, M R Mariani, G Cutrona, M Cilli, F Piccardi, A Daga, G Damonte, E Millo, M Moroni, S Roncella, F Fedeli, L C Boffa, M Ferrarini
    Cancer Gene Therapy, 2009
  • Serum level of CD26 predicts time to first treatment in early B-chronic lymphocytic leukemia
    Stefano Molica, Giovanna Digiesi, Rosanna Mirabelli, Giovanna Cutrona, Anna Antenucci, Matteo Molica, Diana Giannarelli, Isabella Sperduti, Fortunato Morabito, Antonino Neri, Luca Baldini, Manlio Ferrarini
    European Journal of Haematology, 2009
  • Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia
    Fortunato Morabito, Giovanna Cutrona, Massimo Gentile, Serena Matis, Katia Todoerti, Monica Colombo, Claudia Sonaglio, Sonia Fabris, Daniele Reverberi, Mauro Megna, Mauro Spriano, Eugenio Lucia, Edoardo Rossi, Vincenzo Callea, Carla Mazzone, Gianluca Festini, Simonetta Zupo, Stefano Molica, Antonino Neri, Manlio Ferrarini
    British Journal of Haematology, 2009
  • Predictive value of β2-microglobulin (β2-m) levels in chronic lymphocytic leukemia since Binet A stages
    M. Gentile, G. Cutrona, A. Neri, S. Molica, M. Ferrarini, F. Morabito
    Haematologica, 2009
  • Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia
    Stefano Molica, Giovanna Digiesi, Francesca Mauro, Rosanna Mirabelli, Giovanna Cutrona, Gaetano Vitelli, Fortunato Morabito, Francesco Iuliano, Robin Foà, Manlio Ferrarini
    Leukemia Research, 2009
  • CD26 expression in mature B-cell neoplasia: Its possible role as a new prognostic marker in B-CLL
    Lilla Cro, Fortunato Morabito, Nadia Zucal, Sonia Fabris, Marta Lionetti, Giovanna Cutrona, Francesca Rossi, Massimo Gentile, Andrea Ferrario, Manlio Ferrarini, Stefano Molica, Antonino Neri, Luca Baldini
    Hematological Oncology, 2009
  • Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia
    Stefano Molica, Gaetano Vitelli, Giovanna Cutrona, Katia Todoerti, Rosanna Mirabelli, Giovanna Digiesi, Diana Giannarelli, Isabella Sperduti, Matteo Molica, Massimo Gentile, Fortunato Morabito, Antonino Neri, Manlio Ferrarini
    International Journal of Hematology, 2008
  • Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia
    Sonia Fabris, Laura Mosca, Katia Todoerti, Giovanna Cutrona, Marta Lionetti, Daniela Intini, Serena Matis, Monica Colombo, Luca Agnelli, Massimo Gentile, Mauro Spriano, Vincenzo Callea, Gianluca Festini, Stefano Molica, Giorgio Lambertenghi Deliliers, Fortunato Morabito, Manlio Ferrarini, Antonino Neri
    Genes Chromosomes and Cancer, 2008
  • Constitutive expression of IL-12R22 on human multiple myeloma cells delineates a novel therapeutic target
    Irma Airoldi, Claudia Cocco, Nicola Giuliani, Marina Ferrarini, Simona Colla, Emanuela Ognio, Giuseppe Taverniti, Emma Di Carlo, Giovanna Cutrona, Vittorio Perfetti, Vittorio Rizzoli, Domenico Ribatti, Vito Pistoia
    Blood, 2008
  • Clonal heterogeneity in chronic lymphocytic leukemia cells: Superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells
    G. Cutrona, M. Colombo, S. Matis, M. Fabbi, M. Spriano, V. Callea, E. Vigna, M. Gentile, S. Zupo, N. Chiorazzi, F. Morabito, M. Ferrarini
    Haematologica, 2008
  • The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways
    Daniela de Totero, Raffaella Meazza, Matteo Capaia, Marina Fabbi, Bruno Azzarone, Enrico Balleari, Marco Gobbi, Giovanna Cutrona, Manlio Ferrarini, Silvano Ferrini
    Blood, 2008
  • Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia
    Stefano Molica, Gaetano Vitelli, Giovanna Cutrona, Katia Todoerti, Rosanna Mirabelli, Giovanna Digiesi, Fortunato Morabito, Antonino Neri, Manlio Ferrarini
    Leukemia and Lymphoma, 2008
  • Identification of HSP-60 as the specific antigen of IgM produced by BRG-lymphoma cells
    Luca Musante, Massimo Ulivi, Giovanna Cutrona, Nicholas Chiorazzi, Silvio Roncella, Giovanni Candiano, Manlio Ferrarini
    From Genome to Proteome Advances in the Practice Application of Proteomics, 2007
  • Corrigendum to "Lack of mutagenicity and clastogenicity of PNAEμ-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma" [Mutat. Res. 628 (2007) 129-137] (DOI:10.1016/j.mrgentox.2006.11.009)
    L.C. Boffa, P. Menichini, C. Bolognesi, G. Cutrona, S. Roncella, G.L. Damonte, E. Millo, M.R. Mariani, S. Matis, D. Russo, P. Ciliutti, M. Ferrarini
    Mutation Research Genetic Toxicology and Environmental Mutagenesis, 2007
  • Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia
    Stefano Molica, Giovanna Cutrona, Gaetano Vitelli, Rosanna Mirabelli, Matteo Molica, Giovanna Digiesi, Domenico Ribatti, Manlio Ferrarini, Angelo Vacca
    Leukemia Research, 2007
  • CD5+ B cells with the features of subepithelial B cells found in human tonsils
    Mariella Dono, Vito Lelio Burgio, Monica Colombo, Salvatore Sciacchitano, Daniele Reverberi, Vincenzo Tarantino, Giovanna Cutrona, Nicholas Chiorazzi, Manlio Ferrarini
    European Journal of Immunology, 2007
  • B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: Role of ZAP70 determination on bone marrow biopsy specimens
    Elena Sabattini, Rocio Orduz, Cristina Campidelli, Pier Luigi Zinzani, Vincenzo Callea, Simona Zupo, Giovanna Cutrona, Fortunato Morabito, Manlio Ferrarini, Stefano Pileri
    Journal of Clinical Pathology, 2007
  • The peptide nucleic acid targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma lacks immunogenicity: Follow-up characterization of PNAEμ-NLS
    Giovanna Cutrona, Lidia C. Boffa, Maria Rita Mariani, Serena Matis, Gianluca Damonte, Enrico Millo, Silvio Roncella, Manlio Ferrarini
    Oligonucleotides, 2007
  • Lack of mutagenicity and clastogenicity of PNAEμ-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma
    L.C. Boffa, P. Menichini, C. Bolognesi, G. Cutrona, S. Roncella, G.L. Damonte, E. Millo, M.R. Mariani, S. Matis, D. Russo, P. Ciliutti, M. Ferrarini
    Mutation Research Genetic Toxicology and Environmental Mutagenesis, 2007
  • Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc
    L C Boffa, G Cutrona, M Cilli, S Matis, G Damonte, M R Mariani, E Millo, M Moroni, S Roncella, F Fedeli, M Ferrarini
    Cancer Gene Therapy, 2007
  • Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells
    Daniela de Totero, Raffaella Meazza, Simona Zupo, Giovanna Cutrona, Serena Matis, Monica Colombo, Enrico Balleari, Ivana Pierri, Marina Fabbi, Matteo Capaia, Bruno Azzarone, Marco Gobbi, Manlio Ferrarini, Silvano Ferrini
    Blood, 2006
  • B lymphocytes in humans express ZAP-70 when activated in vivo
    Giovanna Cutrona, Monica Colombo, Serena Matis, Daniele Reverberi, Mariella Dono, Vincenzo Tarantino, Nicholas Chiorazzi, Manlio Ferrarini
    European Journal of Immunology, 2006
  • Therapeutically promising PNA complementary to a regulatory sequence for c-myc: Pharmacokinetics in an animal model of human Burkitt's lymphoma
    Lidia C. Boffa, Giovanna Cutrona, Michele Cilli, Maria Rita Mariani, Serena Matis, Martina Pastorino, Gianluca Damonte, Enrico Millo, Silvio Roncella, Manlio Ferrarini
    Oligonucleotides, 2005
  • In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
    Bradley T. Messmer, Davorka Messmer, Steven L. Allen, Jonathan E. Kolitz, Prasad Kudalkar, Denise Cesar, Elizabeth J. Murphy, Prasad Koduru, Manlio Ferrarini, Simona Zupo, Giovanna Cutrona, Rajendra N. Damle, Tarun Wasil, Kanti R. Rai, Marc K. Hellerstein, Nicholas Chiorazzi
    Journal of Clinical Investigation, 2005
  • Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the Eμ enhancer
    Cancer Research, 2003
  • Expression of CD10 by B-chronic lymphocytic leukemia cells undergoing apoptosis in vivo and in vitro
    Haematologica, 2003
  • Role of surface IgM and IgD on survival of the cells from B-cell chronic lymphocytic leukemia [6] (multiple letters)
    Simona Zupo, Giovanna Cutrona, Massimo Mangiola, Manlio Ferrarini
    Blood, 2002
  • CD10 is a marker for cycling cells with propensity to apoptosis in childhood aLL
    G Cutrona, P Tasso, M Dono, S Roncella, M Ulivi, E M Carpaneto, V Fontana, M Comis, F Morabito, M Spinelli, E Frascella, L C Boffa, G Basso, V Pistoia, M Ferrarini
    British Journal of Cancer, 2002
  • Apoptotic cells overexpress vinculin and induce vinculin-specific specific cytotoxic T-cell cross-priming
    Antonella Propato, Giovanna Cutrona, Vittorio Francavilla, Massimo Ulivi, Enrico Schiaffella, Olfert Landt, Rod Dunbar, Vincenzo Cerundolo, Manlio Ferrarini, Vincenzo Barnaba
    Nature Medicine, 2001
  • Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo [5]
    Giovanna Cutrona, Manlio Ferrarini
    Blood, 2001
  • Analysis of stepwise genetic changes in an AIDS-related Burkitt's lymphoma
    Franco Fais, Gilberto Fronza, Silvio Roncella, Alberto Inga, Paola Campomenosi, Giovanna Cutrona, Annalisa Pezzolo, Franco Fedeli, Angelo Abbondandolo, Nicholas Chiorazzi, Vito Pistoia, Manlio Ferrarini
    International Journal of Cancer, 2000
  • Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal
    Giovanna Cutrona, Elisabetta M. Carpaneto, Massimo Ulivi, Silvio Roncella, Olfert Landt, Manlio Ferrarini, Lidia C. Boffa
    Nature Biotechnology, 2000
  • Late Epstein-Barr virus infection of a hepatosplenic γδ T-cell lymphoma arising in a kidney transplant recipient
    Haematologica, 2000
  • Retinoic acid induces persistent, RARα-mediated anti-proliferative responses in Epstein-Barr virus-immortalized B lymphoblasts carrying an activated c-myc oncogene but not in Burkitt's lymphoma cell lines
    Roberta Cariati, Paola Zancai, Michele Quaia, Giovanna Cutrona, Franca Giannini, Silvana Rizzo, Mauro Boiocchi, Riccardo Dolcetti
    International Journal of Cancer, 2000
  • Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo
    Giovanna Cutrona, Nicolò Leanza, Massimo Ulivi, Giovanni Melioli, Vito L. Burgio, Giovanni Mazzarello, Giovanni Gabutti, Silvio Roncella, Manlio Ferrarini
    Blood, 1999
  • Apoptosis induced by crosslinking of CD4 on activated human B cells
    Giovanna Cutrona, Nicolò Leanza, Massimo Ulivi, M.Bernardetta Majolini, Giuseppe Taborelli, Simona Zupo, Cosima T. Baldari, Silvio Roncella, Manlio Ferrarini
    Cellular Immunology, 1999
  • Identification of HSP-60 as the specific antigen of IgM produced by BRG- lymphoma cells
    Luca Musante, Massimo Ulivi, Giovanna Cutrona, Nicholas Chiorazzi, Silvio Roncella, Giovanni Candiano, Manlio Ferrarini
    Electrophoresis, 1999
  • Heterogeneous p53 mutations in a Burkitt lymphoma from an AIDS patient with monoclonal c-myc and VDJ rearrangements
    Paola Campomenosi, Gilberto Fronza, Laura Ottaggio, Silvio Roncella, Alberto Inga, Massimo Bogliolo, Paola Monti, Paola Assereto, Francesca Moro, Giovanna Cutrona, Simonetta Bozzo, Nicholas Chiorazzi, Angelo Abbondandolo, Manlio Ferrarini
    International Journal of Cancer, 1997
  • The patterns of IL2, IFN-γ, IL4 and IL5 gene expression in Hodgkin's disease and reactive lymph nodes are similar
    Haematologica, 1997
  • The propensity to apoptosis of centrocytes and centroblasts correlates with elevated levels of intracellular myc protein
    Giovanna Cutrona, Mariella Dono, Sandra Pastorino, Massimo Ulivi, Vito L. Burgio, Simona Zupo, Silvio Roncella, Manlio Ferrarini
    European Journal of Immunology, 1997
  • C-Myc proto-oncogene expression by germinal center B cells isolated from human tonsils
    GIOVANNA CUTRONA, MARIELLA DONO, SANDRA PASTORINO, MASSIMO ULIVI, VITO LELIO BURGIO, SIMONA ZUPO, SILVIO RONCELLA, MANLIO FERRARINI
    Annals of the New York Academy of Sciences, 1997
  • Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines
    M Loprevite, L Varesco, R Favoni, G Ferrara, F Moro, L Ottaggio, G Fronza, P Campomenosi, A Abbondandolo, G Cutrona, S Roncella, A Albini, M Aluigi, S Pozzi, C Pera, R Biticchi, V Gismondi, F Grossi, M Pennucci, A Ardizzoni
    International Journal of Oncology, 1997
  • Lymphoblastoid cells transfected with c-myc: Downregulation of EBV-lytic antigens and impaired response of autologous CD4+ T cells in vitro
    Franco Fais, Giovanna Cutrona, Massimo Ulivi, Silvio Roncella, M. Cristina Gagliardi, Paolo Cornaglia-Ferraris, Martin Rowe, Vincenzo Barnaba, Manlio Ferrarini
    International Journal of Cancer, 1996
  • Apoptosis of Burkitt's lymphoma cells induced by specific interaction of surface IgM with a self-antigen: Implications for lymphomagenesis in acquired immunodeficiency syndrome
    S Roncella, G Cutrona, A Favre, M Ulivi, F Fais, A Signorini, CE Grossi, N Chiorazzi, M Ferrarini
    Blood, 1996
  • Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts
    Journal of Experimental Medicine, 1995
  • A retinoic acid resistant HL-60 cell clone sensitive to n-(4-hydroxyphenyl) retinamide-mediated clonal growth inhibition
    Claudio Brigati, Nicoletta Ferrari, Mauro Megna, Silvio Roncella, Giovanna Cutrona, Francesca Tosettf, Giorgio Vidali
    Leukemia and Lymphoma, 1995
  • Production of inflammatory cytokines by Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines spontaneously originated from the peripheral blood of patients with human immunodeficiency virus (HIV) infection
    Silvio Roncella, Lucia Baldi, Giovanna Cutrona, Maurizio Viale, Fortunato Rizzo, Milena Gasco, Manlio Ferrarini, Vito Pistoia
    Clinical Immunology and Immunopathology, 1995
  • Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus
    Journal of Immunology, 1994
  • Transforming growth factor beta‐1 (TGF‐β1) released by an Epstein‐Barr virus (EBV) positive spontaneous lymphoblastoid cell line from a patient with Kostmann's congenital neutropenia inhibits the growth of normal committed haemopoietic progenitors in vitro
    A. Corcione, S. Roncella, G. Cutrona, P. G. Mori, M. Ferrarini, V. Pistoia
    British Journal of Haematology, 1993
  • H and l ferritin gene expression in u937 cells induced to macrophage differentiation
    Giovanna Bianchi-scarrá, Marco Musso, Cecilia Garré, Giovanna Cutrona, Paola Fiorentini, Daniela Zarcone, Vito Pistoia
    Leukemia and Lymphoma, 1993
  • Cytogenetic rearrangement of c-MYC oncogene occurs prior to infection with epstein-Barr virus in the monoclonal malignant b cells from an AIDS patient
    Silvio Roncella, Paola Francia Di Celle, Giovanna Cutrona, Anna Carbone, Mario Sessarego, Giuseppe Landonio, Robin Foà, Martin Rowe, Manlio Ferrarini
    Leukemia and Lymphoma, 1993
  • Characterization of EBV-positive lymphoblastoid cell lines obtained from HIV seropositive patients with or without lymphomas
    Leukemia, 1992
  • Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: Evidence for the single-cell origin of the two tumors
    V Pistoia, S Roncella, PF Di Celle, M Sessarego, G Cutrona, G Cerruti, GP Boccaccio, CE Grossi, R Foa, M Ferrarini
    Blood, 1991
  • Cellular and molecular characterization of two cases of castleman's disease, plasma cell variant
    Silvio Roncella, Paola Francia Di Celle, Emanuele S. G. D'amore, Claudio Casoli, Giovanna Cutrona, Carlo Muzzulini, Federico Quaini, Guido Nicolo, Robert Foa, Vito Pistoia
    Leukemia and Lymphoma, 1991
  • Assessment of the potential malignancy of Epstein-Barr virus (EBV)-infected B cells in AIDS-related disorders.
    Cancer Detection and Prevention, 1990
  • Studies on the oncogenic potential of epstein‐barr‐virus (EBV)‐infected B cells in aids‐related disorders
    Silvio Roncella, Patrizia Caretto, Guido Forni, Giovanna Cutrona, Antimo Verde, Dunia Ramarli, Paola Francia Di Celle, Robin Foà, Mario Sessarego, Vito Pistoia, Manlio Ferrarini
    International Journal of Cancer, 1989

RECENT SCHOLAR PUBLICATIONS

  • Immunogenetic Architecture of Chronic Lymphocytic Leukemia at Early Stage: Insights from the O-CLL1 Cohort
    D Bagnara, AN Mazzarello, M Colombo, E Nano, N Cardente, F Ferrero, ...
    Antibodies 15 (2), 25 , 2026
    2026
  • Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia
    M Cardillo, F Ferrero, N Bertola, E Nano, R Massara, MC Capra, ...
    International Journal of Molecular Sciences 27 (3), 1202 , 2026
    2026
  • To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy
    EA Martino, S Caserta, E Vigna, G Cutrona, A Bruzzese, F Mendicino, ...
    European Journal of Haematology , 2026
    2026
  • Asymmetric induction of IL-23R by CpG and IL-15 in proliferative CLL fractions highlights intraclonal heterogeneity in chronic lymphocytic leukemia
    M Cardillo, N Bertola, F Ferrero, R Massara, MC Capra, D Reverberi, ...
    bioRxiv, 2025.08. 27.672649 , 2025
    2025
  • Targeting the p53/xCT/GSH Axis with PRIMA-1 Met Combined with Sulfasalazine Shows Therapeutic Potential in Chronic Lymphocytic Leukemia
    M Pasino, A Speciale, S Ravera, G Cutrona, R Massara, N Bertola, ...
    International Journal of Molecular Sciences 26 (12), 5559 , 2025
    2025
    Citations: 2
  • Regulation of mitochondrial metabolism by IL12-family cytokines in chronic lymphocytic leukemia: A novel perspective on therapeutic resistance
    N Bertola, F Ferrero, V Cossu, E Nano, M Colombo, R Massara, ...
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 55 , 2025
    2025
  • MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study
    E Nano, F Reggiani, AA Amaro, P Monti, M Colombo, N Bertola, F Ferrero, ...
    Non-coding RNA 10 (5), 46 , 2024
    2024
    Citations: 2
  • Unexpected chronic lymphocytic leukemia B cell activation by bisphosphonates
    AN Mazzarello, E Gugiatti, V Cossu, N Bertola, D Bagnara, S Carta, ...
    Cancer Immunology, Immunotherapy 73 (2), 27 , 2024
    2024
  • Unraveling the bone tissue microenvironment in chronic lymphocytic leukemia
    P Giannoni, C Marini, G Cutrona, GM Sambuceti, F Fais, D de Totero
    Cancers 15 (20), 5058 , 2023
    2023
    Citations: 12
  • Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
    F Morabito, C Adornetto, P Monti, A Amaro, F Reggiani, M Colombo, ...
    Frontiers in oncology 13, 1198992 , 2023
    2023
    Citations: 20
  • The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia
    F Morabito, G Tripepi, FR Mauro, L Laurenti, G Reda, R Moia, ...
    American Journal of Hematology 98 (7), E157-E160 , 2023
    2023
    Citations: 1
  • Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy
    S Galimberti, A Neri, C Adornetto, F Morabito, C Adornetto, P Monti, ...
    2023
  • A high percentage of CD16+ monocytes correlates with the extent of bone erosion in chronic lymphocytic leukemia patients: The impact of leukemic B cells in monocyte …
    P Giannoni, C Marini, G Cutrona, K Todoerti, A Neri, A Ibatici, ...
    Cancers 14 (23), 5979 , 2022
    2022
    Citations: 8
  • The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study
    G De Luca, G Cerruti, S Lastraioli, R Conte, A Ibatici, N Di Felice, ...
    Hematological Oncology 40 (5), 962-975 , 2022
    2022
    Citations: 6
  • Old and new facts and speculations on the role of the B cell receptor in the origin of chronic lymphocytic leukemia
    D Bagnara, AN Mazzarello, F Ghiotto, M Colombo, G Cutrona, F Fais, ...
    International Journal of Molecular Sciences 23 (22), 14249 , 2022
    2022
    Citations: 24
  • MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells
    S Matis, A Grazia Recchia, M Colombo, M Cardillo, M Fabbi, K Todoerti, ...
    Blood Advances 6 (20), 5593-5612 , 2022
    2022
    Citations: 17
  • Characterizing features of human circulating B cells carrying CLL-like stereotyped immunoglobulin rearrangements
    D Bagnara, M Colombo, D Reverberi, S Matis, R Massara, N Cardente, ...
    Frontiers in oncology 12, 894419 , 2022
    2022
    Citations: 13
  • LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells
    S Matis, M Rossi, L Brondolo, M Cardillo, D Reverberi, R Massara, ...
    Hematological Oncology 40 (1), 41-48 , 2022
    2022
    Citations: 10
  • Lymphocyte doubling time as a key prognostic factor to predict time to first treatment in early-stage chronic lymphocytic leukemia
    F Morabito, G Tripepi, R Moia, AG Recchia, P Boggione, FR Mauro, ...
    Frontiers in oncology 11, 684621 , 2021
    2021
    Citations: 17
  • TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
    F Morabito, G Del Poeta, FR Mauro, G Reda, P Sportoletti, L Laurenti, ...
    American Journal of Hematology 96 (8), E306-E310 , 2021
    2021
    Citations: 20

MOST CITED SCHOLAR PUBLICATIONS

  • In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
    BT Messmer, D Messmer, SL Allen, JE Kolitz, P Kudalkar, D Cesar, ...
    The Journal of clinical investigation 115 (3), 755-764 , 2005
    2005
    Citations: 879
  • CD38 and chronic lymphocytic leukemia: a decade later
    F Malavasi, S Deaglio, R Damle, G Cutrona, M Ferrarini, N Chiorazzi
    Blood, The Journal of the American Society of Hematology 118 (13), 3470-3478 , 2011
    2011
    Citations: 338
  • Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal
    G Cutrona, EM Carpaneto, M Ulivi, S Roncella, O Landt, M Ferrarini, ...
    Nature biotechnology 18 (3), 300-303 , 2000
    2000
    Citations: 322
  • International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
    A Condoluci, L Terzi di Bergamo, P Langerbeins, MA Hoechstetter, ...
    Blood, The Journal of the American Society of Hematology 135 (21), 1859-1869 , 2020
    2020
    Citations: 195
  • Selective expansion of cytotoxic T lymphocytes with a CD4 + CD56 + surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients …
    V Barnaba, A Franco, M Paroli, R Benvenuto, G De Petrillo, VL Burgio, ...
    The Journal of Immunology 152 (6), 3074-3087 , 1994
    1994
    Citations: 181
  • Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells
    D de Totero, R Meazza, S Zupo, G Cutrona, S Matis, M Colombo, ...
    Blood 107 (9), 3708-3715 , 2006
    2006
    Citations: 170
  • The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways
    D de Totero, R Meazza, M Capaia, M Fabbi, B Azzarone, E Balleari, ...
    Blood, The Journal of the American Society of Hematology 111 (2), 517-524 , 2008
    2008
    Citations: 146
  • The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage …
    S Molica, TD Shanafelt, D Giannarelli, M Gentile, R Mirabelli, G Cutrona, ...
    American journal of hematology 91 (11), 1090-1095 , 2016
    2016
    Citations: 126
  • Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia
    D Ronchetti, L Mosca, G Cutrona, G Tuana, M Gentile, S Fabris, L Agnelli, ...
    BMC medical genomics 6 (1), 27 , 2013
    2013
    Citations: 114
  • Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
    P Monti, P Menichini, A Speciale, G Cutrona, F Fais, E Taiana, A Neri, ...
    Frontiers in oncology 10, 593383 , 2020
    2020
    Citations: 113
  • Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming
    A Propato, G Cutrona, V Francavilla, M Ulivi, E Schiaffella, O Landt, ...
    Nature medicine 7 (7), 807-813 , 2001
    2001
    Citations: 104
  • Predictive value of β2-microglobulin (β2-m) levels in chronic lymphocytic leukemia since Binet A stages
    M Gentile, G Cutrona, A Neri, S Molica, M Ferrarini, F Morabito
    Haematologica 94 (6), 887 , 2009
    2009
    Citations: 102
  • Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients
    M Gentile, TD Shanafelt, D Rossi, L Laurenti, FR Mauro, S Molica, ...
    Blood, The Journal of the American Society of Hematology 128 (16), 2093-2095 , 2016
    2016
    Citations: 97
  • Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features
    F Morabito, L Mosca, G Cutrona, L Agnelli, G Tuana, M Ferracin, B Zagatti, ...
    Clinical cancer research 19 (21), 5890-5900 , 2013
    2013
    Citations: 96
  • Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo
    G Cutrona, N Leanza, M Ulivi, G Melioli, VL Burgio, G Mazzarello, ...
    Blood, The Journal of the American Society of Hematology 94 (9), 3067-3076 , 1999
    1999
    Citations: 94
  • Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion
    L Mosca, S Fabris, M Lionetti, K Todoerti, L Agnelli, F Morabito, G Cutrona, ...
    Clinical Cancer Research 16 (23), 5641-5653 , 2010
    2010
    Citations: 92
  • Molecular and transcriptional characterization of 17p loss in B‐cell chronic lymphocytic leukemia
    S Fabris, L Mosca, K Todoerti, G Cutrona, M Lionetti, D Intini, S Matis, ...
    Genes, Chromosomes and Cancer 47 (9), 781-793 , 2008
    2008
    Citations: 84
  • B lymphocytes in humans express ZAP‐70 when activated in vivo
    G Cutrona, M Colombo, S Matis, D Reverberi, M Dono, V Tarantino, ...
    European journal of immunology 36 (3), 558-569 , 2006
    2006
    Citations: 81
  • Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia
    S Fabris, V Bollati, L Agnelli, F Morabito, V Motta, G Cutrona, S Matis, ...
    Epigenetics 6 (2), 188-194 , 2011
    2011
    Citations: 80
  • microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters
    M Negrini, G Cutrona, C Bassi, S Fabris, B Zagatti, M Colombo, ...
    Clinical Cancer Research 20 (15), 4141-4153 , 2014
    2014
    Citations: 75